Finance

FoldRx Pharmaceuticals closes $43 million Series B financing

Published in Gene Therapy Weekly, June 29th, 2006

FoldRx Pharmaceuticals, Inc., a development-stage biotechnology company focused on protein misfolding diseases, announced that it has successfully raised $43 million in a Series B financing.

The funds will be used for the continued clinical development of FoldRx's lead clinical candidate, Fx-1006A, and to advance its pipeline, which is initially focused on hereditary amyloidosis and neurodegenerative diseases, including Parkinson disease. Texas Pacific Group (TPG) Ventures and Alta Partners led the Series B round, which also included Novartis BioVenture Fund, as well as original investors, HealthCare Ventures and Fidelity Biosciences.

"Therapeutics...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry